In this installment of the “How I treat ...” series in Blood, the authors note that few patients with primary refractory or resistant acute myeloid leukemia (AML) can be cured with conventional salvage therapy, and they should therefore be evaluated for allogeneic hematopoietic cell transplantation (HCT). Many novel therapies under evaluation – i.e., tyrosine kinase inhibitors, small-molecule inhibitors, antibody-based therapies, and cell-based therapies – are reviewed, which the authors indicate are likely to enter clinical practice as a bridge to transplant and/or for older, unfit patients who are not candidates for allogeneic HCT.
Review: Treating Early Relapsed and Refractory AML
Aug 2015